V. Blanchette

发表

Comparing the burden of illness of haemophilia between resource‐constrained and unconstrained countries: the São Paulo–Toronto Hemophilia Study

J. Carneiro, V. Blanchette, M. Ozelo, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Front & Back Matter

W. Wiersinga, G. Kahaly, V. Blanchette, 2018, Ophthalmic Research.

Definitions in hemophilia: communication from the SSC of the ISTH

R. Ljung, V. Blanchette, N. Key, 2014, Journal of thrombosis and haemostasis : JTH.

Meeting unmet needs in inhibitor patients

V. Blanchette, M. Manco‐Johnson, V. Blanchette, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Canadian multi‐institutional survey of immune tolerance therapy (ITT) – experience with the use of recombinant factor VIII for ITT

V. Blanchette, M. Carcao, M. Poon, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Inhibitor development, immune tolerance and prophylaxis in haemophilia A – the need for an evidence‐based approach

P. Mannucci, E. Santagostino, V. Blanchette, 2006, Haemophilia.

Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology.

J. George, G. Raskob, S. Woolf, 1996, Blood.

Management of chronic immune thrombocytopenic purpura in children and adults.

J. Freedman, V. Blanchette, B. Garvey, 1998, Seminars in hematology.

Hepatitis A and B immunization for individuals with inherited bleeding disorders

V. Blanchette, A. Stain, L. Ford-Jones, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Is morphine exposure associated with acute chest syndrome in children with vaso-occlusive crisis of sickle cell disease? A 6-year case-crossover study.

G. Koren, D. Juurlink, V. Blanchette, 2007, Clinical therapeutics.

Genotype–phenotype correlation in children with hereditary spherocytosis

V. Blanchette, M. Carcao, J. Langer, 2020, British journal of haematology.

Assessment of thrombocytopenic disorders using the Platelet Function Analyzer (PFA‐100®) *

V. Blanchette, M. Carcao, D. Christie, 2002, British journal of haematology.

Factor product utilization and health outcomes in patients with haemophilia A and B on extended half‐life concentrates: A Canadian observational study of real‐world outcomes

A. Iorio, V. Blanchette, M. Carcao, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Platelet Activation and von Willebrand Factor Binding to Platelets in Newborn Infants with Central Venous Lines

J. Freedman, V. Blanchette, M. Albisetti, 2006, Acta Haematologica.

The Relationship of von Willebrand Factor Binding to Activated Platelets from Healthy Neonates and Adults

J. Freedman, V. Blanchette, K. Amankwah, 2003, Pediatric Research.

Induction of a secondary human anti‐HLA alloimmune response in severe combined immunodeficient mice engrafted with human lymphocytes

J. Freedman, V. Blanchette, A. Lazarus, 1997, Transfusion.

White cell depletion of red cell and pooled random‐donor platelet concentrates by filtration and residual lymphocyte subset analysis

J. Freedman, V. Blanchette, M. Garvey, 1991, Transfusion.

National survey of neonatal transfusion practices: II. Blood component therapy.

M. Albanese, R. Strauss, V. Blanchette, 1993, Pediatrics.

Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH

E. Neufeld, A. Iorio, J. Blatny, 2017, Journal of thrombosis and haemostasis : JTH.

Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia

M. Morfini, V. Blanchette, K. Fischer, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Towards comprehensive care in transition for young people with haemophilia

V. Blanchette, V. Breakey, P. Bolton-Maggs, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens

K. Fischer, G. Spotts, V. Blanchette, 2010, Journal of thrombosis and haemostasis : JTH.

Childhood immune thrombocytopenic purpura: diagnosis and management.

V. Blanchette, P. Bolton-Maggs, 2010, Hematology/oncology clinics of North America.

Genetic determinants of VWF clearance and FVIII-binding modify FVIII pharmacokinetics in pediatric hemophilia A patients.

V. Blanchette, M. Carcao, W. Hopman, 2019, Blood.

Joint health and functional ability in children with haemophilia who receive intensive replacement therapy

P. Helders, V. Blanchette, A. Abad, 2011, Haemophilia.

Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: Validity of the hemophilia joint health score

R. Engelbert, V. Blanchette, A. Abad, 2011, Arthritis care & research.

Long-term outcomes after splenectomy in children with immune thrombocytopenia: an update on the registry data from the Intercontinental Cooperative ITP Study Group.

V. Blanchette, E. Pullenayegum, M. L. Avila, 2019, Haematologica.

Platelet transfusion therapy in newborn infants.

V. Blanchette, J. Hellmann, T. Kühne, 1995, Transfusion medicine reviews.

Prophylaxis in the haemophilia population

V. Blanchette, V. Blanchette, 2010, Haemophilia.

Severity and Features of Epistaxis in Children with a Mucocutaneous Bleeding Disorder

V. Blanchette, P. James, T. Biss, 2017, The Journal of pediatrics.

Quantitation of bleeding symptoms in children with von Willebrand disease: use of a standardized pediatric bleeding questionnaire

V. Blanchette, P. James, D. Lillicrap, 2010, Journal of thrombosis and haemostasis : JTH.

‘Train‐the‐Trainer’: an effective and successful model to accelerate training and improve physiotherapy services for persons with haemophilia in China

V. Blanchette, M. Poon, J. Sun, 2014, Haemophilia.

Platelet disorders in children: A diagnostic approach

S. Israels, V. Blanchette, G. Rivard, 2011, Pediatric blood & cancer.

REVIEW Platelet Disorders in Children: A Diagnostic Approach

S. Israels, V. Blanchette, G. Rivard, 2011 .

Phosphatidylserine exposure, microparticle formation and mitochondrial depolarisation in Glanzmann thrombasthenia platelets

V. Blanchette, A. Nurden, M. Rand, 2014, Thrombosis and Haemostasis.

The prevention and management of infections in children with asplenia or hyposplenia.

V. Blanchette, E. Ford-Jones, V. Price, 2007, Infectious disease clinics of North America.

The prevention and treatment of bacterial infections in children with asplenia or hyposplenia: Practice considerations at the Hospital for Sick Children, Toronto

V. Blanchette, J. Langer, S. Dutta, 2006, Pediatric Blood & Cancer.

Platelet and immune responses to oral cyclic dexamethasone therapy in childhood chronic immune thrombocytopenic purpura.

J. Freedman, V. Blanchette, T. Kühne, 1997, The Journal of pediatrics.

Comparison of Plasma Exchange With Plasma Infusion in the Treatment of Thrombotic Thrombocytopenia Purpura

J. Kelton, V. Blanchette, R. Spasoff, 1992 .

A Quality Improvement Bundle to Improve Informed Choice for Children With Typical, Newly Diagnosed Immune Thrombocytopenia

V. Blanchette, M. Carcao, S. Porter, 2018, Journal of pediatric hematology/oncology.

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.

J. George, J. Bussel, V. Blanchette, 2009, Blood.

Ultrasound and magnetic resonance imaging of healthy paediatric ankles and knees: a baseline for comparison with haemophilic joints

R. Moineddin, K. Lakshmi, V. Blanchette, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Essential thrombocythaemia in children

V. Blanchette, Y. Dror, 1999, British journal of haematology.

Essential thrombocythemia in children.

A. Zipursky, V. Blanchette, Y. Dror, 1999, Journal of pediatric hematology/oncology.

V. Blanchette, B. Feldman, A. Stain, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

Pharmacokinetic studies of coagulation factors: relevance of plasma and extracellular volume and body weight

V. Blanchette, P. Komwilaisak, V. Blanchette, 2006 .

Random donor platelet crossmatching: Comparison of four platelet antibody detection methods

V. Blanchette, M. Garvey, A. Hornstein, 1988, American journal of hematology.

Haemophilia

V. Blanchette, K. Fischer, A. Shapiro, 1937, Nature Reviews Disease Primers.

Childhood Chronic Immune Thrombocytopenic Purpura: Unresolved Issues

V. Blanchette, V. Price, 2003, Journal of pediatric hematology/oncology.

Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations

E. Neufeld, A. Iorio, J. Blatny, 2018, Research and practice in thrombosis and haemostasis.

Inherited bleeding disorders.

V. Blanchette, C. Turner, C. Sparling, 1991, Bailliere's clinical haematology.

Guest Editorial: Intravenous Immunoglobulin: More Questions Than Answers

V. Blanchette, R. Sacher, 1991 .

Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity.

J. Freedman, V. Blanchette, J. Semple, 1996, Blood.

von Willebrand Disease in a Pediatric-based Population - Comparison of Type 1 Diagnostic Criteria and Use of the PFA-100® and a von Willebrand Factor/Collagen-binding Assay

V. Blanchette, M. Carcao, D. Lillicrap, 2000, Thrombosis and Haemostasis.

Desmopressin (DDAVP) Responsiveness in Children With von Willebrand Disease

V. Blanchette, M. Carcao, S. Revel-Vilk, 2003, Journal of pediatric hematology/oncology.

Antibody‐mediated inhibition of the human alloimmune response to platelet transfusion in Hu‐PBL‐SCID mice

J. Freedman, V. Blanchette, A. Lazarus, 1999, British journal of haematology.

Immune thrombocytopenic purpura [6] (multiple letters)

V. Blanchette, D. Cines, W. Dzik, 2002 .

Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference

J. Astermark, J. Oldenburg, C. Leissinger, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Heparin Therapy in Pediatric Patients: A Prospective Cohort Study

W. Williams, P. Brill-Edwards, V. Blanchette, 1994, Pediatric Research.

Triple heterozygosity in the integrin αIIb subunit in a patient with Glanzmann's thrombasthenia

J. Freedman, V. Blanchette, B. Jacquelin, 2004, Journal of thrombosis and haemostasis : JTH.

Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report

P. Noris, A. Srivastava, V. Blanchette, 2019, HemaSphere.

Front & Back Matter

V. Blanchette, L. Brandão, V. Breakey, 2017, Intervirology.

A survey of factor prophylaxis in the Canadian haemophilia A population

S. Israels, V. Blanchette, G. Rivard, 2004, Haemophilia.

Definitions for haemophilia prophylaxis and its outcomes: The Canadian Consensus Study

V. Blanchette, M. Carcao, E. Paradis, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Initial Bone Marrow Aspiration in Childhood Idiopathic Thrombocytopenia: Decision Analysis

G. Naglie, V. Blanchette, M. Krahn, 2001, Journal of pediatric hematology/oncology.

Fcγ receptor IIa and IIIa polymorphisms in childhood immune thrombocytopenic purpura

V. Blanchette, M. Carcao, G. Denomme, 2003 .

Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement

A. Iorio, E. Iserman, J. Oldenburg, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Childhood chronic immune thrombocytopenic purpura (ITP).

V. Blanchette, 2002, Blood reviews.

Immune thrombocytopenic purpura.

V. Blanchette, D. Cines, 2002, The New England journal of medicine.

A prospective, longitudinal study of central venous catheter‐related deep venous thrombosis in boys with hemophilia

A. Daneman, V. Blanchette, M. Carcao, 2004, Journal of thrombosis and haemostasis : JTH.

Definitions in Hemophilia: Resolved and Unresolved Issues

V. Blanchette, A. Srivastava, A. Srivastava, 2015, Seminars in Thrombosis & Hemostasis.

DDAVP challenge tests in boys with mild/moderate haemophilia A *

V. Blanchette, M. Carcao, S. Revel-Vilk, 2002, British Journal of Haematology.

Using Value-of-Information Methods when the Disease Is Rare and the Treatment Is Expensive—The Example of Hemophilia A

J. Beyene, A. Willan, V. Blanchette, 2013, Journal of General Internal Medicine.

The Jamaican Haemophilia Registry: Describing the burden of disease

V. Blanchette, N. Young, A. Abad, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

National survey of neonatal transfusion practices: I. Red blood cell therapy.

M. Albanese, R. Strauss, V. Blanchette, 1993, Pediatrics.

Flow cytometric evaluation of platelet activation in blood collected into EDTA vs. Diatube‐H, a sodium citrate solution supplemented with theophylline, adenosine, and dipyridamole

J. Freedman, V. Blanchette, T. Kühne, 1995, American journal of hematology.

Correlating clinical and radiological assessment of joints in haemophilia: results of a cross sectional study

V. Blanchette, B. Feldman, A. Srivastava, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Treatment of hemophilia: recombinant clotting factors

V. Blanchette, D. Lillicrap, C. Sabapathy, 2014 .

Consensus perspectives on prophylactic therapy for haemophilia: summary statement

J. Astermark, P. Giangrande, R. Ljung, 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors

L. Valentino, R. Ljung, V. Blanchette, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: pharmacokinetic characteristics.

W. Evans, G. Koren, A. Zipursky, 1996, Medical and pediatric oncology.

Thrombocytopenia and thromboembolism in pediatric systemic lupus erythematosus.

E. Silverman, V. Blanchette, S. Revel-Vilk, 2003, The Journal of pediatrics.

Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura

V. Blanchette, M. Bernstein, N. Kobrinsky, 1994, The Lancet.

A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura.

M. Gent, V. Blanchette, M. Andrew, 1993, The Journal of pediatrics.

Imaging of haemophilic arthropathy in growing joints: pitfalls in ultrasound and MRI

V. Blanchette, A. Mohanta, A. Doria, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Unique processing pathways within recipient antigen-presenting cells determine IgG immunity against donor platelet MHC antigens.

J. Freedman, V. Blanchette, J. Semple, 2000, Blood.

Recipient humoral immunity against leukoreduced allogeneic platelets is suppressed by aminoguanidine, a selective inhibitor of inducible nitric oxide synthase.

J. Freedman, V. Blanchette, J. Semple, 1996, Blood.

Personalising haemophilia management with shared decision making

L. Valentino, V. Blanchette, C. Négrier, 2021, The Journal of Haemophilia Practice.

Reticulated Platelet Counts in the Diagnosis of Acute Immune Thrombocytopenic Purpura

V. Blanchette, S. Butchart, B. Saxon, 1998, Journal of pediatric hematology/oncology.

Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura.

S. Vesely, E. Neufeld, V. Blanchette, 2008, Blood.

Splenectomy in children with idiopathic thrombocytopenic purpura: A prospective study of 134 children from the Intercontinental Childhood ITP Study Group

R. Tamminga, V. Blanchette, T. Kühne, 2007, Pediatric blood & cancer.

Factors that influence lymphocyte yields in lymphocytapheresis

V. Blanchette, G. Rock, N. McCombie, 1985, Transfusion.

Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience

V. Blanchette, M. Carcao, M. Poon, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Permeabilization and fixation conditions for intracellular flow cytometric detection of the T-cell receptor zeta chain and other intracellular proteins in lymphocyte subpopulations.

J. Freedman, V. Blanchette, A. Lazarus, 1998, Cytometry.

Childhood immune thrombocytopenia: a changing therapeutic landscape.

V. Blanchette, V. Breakey, 2011, Seminars in thrombosis and hemostasis.

A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia.

Yow-Ming C Wang, J. Bussel, V. Blanchette, 2011, Blood.

primary immune thrombocytopenia International consensus report on the investigation and management of

V. Blanchette, D. Cines, B. Chong, 2010 .

Consensus recommendations for use of central venous access devices in haemophilia

L. Valentino, V. Blanchette, A. Shapiro, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Use of the PFA-100® in the Assessment of Primary, Platelet-Related Hemostasis in a Pediatric Setting

V. Blanchette, M. Carcao, M. Rand, 1998, Seminars in thrombosis and hemostasis.

Experience with central venous access devices (CVADs) in the Canadian hemophilia primary prophylaxis study (CHPS)

S. Israels, V. Blanchette, R. Klaassen, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Overview of the use of implantable venous access devices in the management of children with inherited bleeding disorders

V. Blanchette, B. Connolly, P. Komvilaisak, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Central venous access devices in children with hemophilia: an update.

V. Blanchette, A. Stain, A. Al-Musa, 1997, Blood Coagulation and Fibrinolysis.

Central venous access catheters in children with haemophilia.

V. Blanchette, R. Filler, A. Stain, 1996, Blood Coagulation and Fibrinolysis.

Patterns of bruising in preschool children with inherited bleeding disorders: a longitudinal study

F. Dunstan, V. Blanchette, A. Kemp, 2016, Archives of Disease in Childhood.

Maternal DRB1*1501, DQA1*0102, DQB1*0602 haplotype in fetomaternal alloimmunization against human platelet alloantigen HPA-6b (GPIIIa-Gln489).

V. Blanchette, R. Kekomäki, L. Porcelijn, 1997, Tissue antigens.

Introducing the Tran Qol: A New Disease-Specific Quality of Life Measure for Children and Adults with Thalassemia Major

S. Alibhai, V. Blanchette, N. Young, 2013 .

The genetics of Canadian type 3 von Willebrand disease: further evidence for co‐dominant inheritance of mutant alleles

V. Blanchette, J. Leggo, P. James, 2013, Journal of thrombosis and haemostasis : JTH.

Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic‐guided prophylaxis

G. Spotts, L. Valentino, V. Blanchette, 2016, Haemophilia.

Abnormalities of the peripheral blood as a presenting feature of immunodeficiency

V. Blanchette, J. Winkelstein, W. Zinkham, 1978, American journal of hematology.

Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort.

P. Babyn, S. Israels, V. Blanchette, 2018, The Lancet. Haematology.

Use of ultrasound for assessment of musculoskeletal disease in persons with haemophilia: Results of an International Prophylaxis Study Group global survey

P. Babyn, E. Chang, V. Blanchette, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

J. Kelton, V. Blanchette, R. Spasoff, 1991, The New England journal of medicine.

Inhibition of a secondary human alloimmune response via the soluble active component of CD154 (CD40L) in severe combined immune‐deficient mice engrafted with human lymphocytes

J. Freedman, V. Blanchette, A. Lazarus, 1999, Transfusion.

Hematological Problems in Pediatric Intensive Care

V. Blanchette, S. Revel-Vilk, N. Robitaille, 2014 .

Pharmacokinetic modelling and validation of the half‐life extension needed to reduce the burden of infusions compared with standard factor VIII

C. Hermans, E. Santagostino, V. Blanchette, 2018, Haemophilia.

Commentary on small‐volume red cell transfusions for neonatal patients

R. Strauss, V. Blanchette, H. Hume, 1990, Transfusion.

Acquired von Willebrand disease in Wilms' tumor patients.

M. Coppes, V. Blanchette, A. Poon, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

19. Work-Up of a Bleeding Child

V. Blanchette, M. D. and, 2014 .

Work‐Up of a Bleeding Child

V. Blanchette, M. Carcao, 2010 .

Extreme leukoreduction of major histocompatibility complex class II positive B cells enhances allogeneic platelet immunity.

J. Freedman, V. Blanchette, A. Lazarus, 1999, Blood.

Recipient Immune Responses Induced by Allogeneic Whole Blood or Platelet Transfusions: Implications for Immunomodulation

J. Freedman, V. Blanchette, J. Semple, 1997 .

Concurrent RhGM‐CSF does not offset myelosuppression from intensive chemotherapy: Randomized placebo‐controlled study in childhood acute lymphoblastic leukemia

Mark L. Greenberg, A. Zipursky, M. Freedman, 1994, American journal of hematology/oncology.

Platelet activation induced by porcine factor VIII (HYATE:C)

V. Blanchette, A. Lazarus, J. Teitel, 1998, American journal of hematology.

Analysis of platelets by flow cytometry.

J. Freedman, V. Blanchette, A. Lazarus, 1995, Transfusion science.

Oral vitamin E supplementation for the prevention of anemia in premature infants: a controlled trial.

E. Bell, A. Zipursky, V. Blanchette, 1987, Pediatrics.

Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight.

G. Spotts, V. Blanchette, K. Fischer, 2012, Blood.

Combined De-Novo Mutation and Non-Random X-Chromosome Inactivation Causing Wiskott-Aldrich Syndrome in a Female with Thrombocytopenia

S. Scherer, H. Ochs, T. Torgerson, 2013, Journal of Clinical Immunology.

Establishing physician to patient ratios and predicting workforce needs for Canadian pediatric hematology‐oncology programs

V. Blanchette, D. Strother, J. Halton, 2013, Pediatric blood & cancer.

Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein

J. Dumont, J. Oldenburg, V. Blanchette, 2018, Haemophilia.

The application of bypassing‐agent prophylaxis in haemophilia A patients with inhibitors: a meeting report

L. Valentino, C. Leissinger, V. Blanchette, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

A prospective study of health‐related quality of life of boys with severe haemophilia A in China: comparing on‐demand to prophylaxis treatment

V. Blanchette, N. Young, M. Poon, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Outcome measures in haemophilia: more than just factor levels

M. Bullinger, V. Blanchette, W. Schramm, 2004, Haemophilia.

Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study

A. Raj, J. Bussel, V. Blanchette, 2016, The Lancet.

Observational Study of Real-World Factor Utilization and Health Outcomes in Patients with Hemophilia in Canada

A. Iorio, V. Blanchette, R. Klaassen, 2018, Blood.

Indirect allorecognition of platelets by T helper cells during platelet transfusions correlates with anti-major histocompatibility complex antibody and cytotoxic T lymphocyte formation.

J. Freedman, V. Blanchette, J. Semple, 1995, Blood.

Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials

G. Spotts, V. Blanchette, K. Fischer, 2011, Haemophilia.

Neonatal alloimmune thrombocytopenia due to a new platelet-specific alloantibody.

V. Blanchette, R. Aster, P. Newman, 1993, Blood.

Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method

G. Spotts, V. Blanchette, C. Négrier, 2004 .

Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-18, 2003, Birmingham, UK.

G. Spotts, V. Blanchette, C. Négrier, 2004, Seminars in hematology.

Optimizing factor prophylaxis for the haemophilia population: where do we stand?

R. Ljung, E. Santagostino, V. Blanchette, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Musculoskeletal ultrasound in hemophilia: Results and recommendations from a global survey and consensus meeting

P. Babyn, E. Chang, V. Blanchette, 2021, Research and practice in thrombosis and haemostasis.

Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective

P. Babyn, V. Blanchette, M. Carcao, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Diagnostic accuracy of ultrasound for assessment of hemophilic arthropathy: MRI correlation.

R. Moineddin, V. Blanchette, A. Mohanta, 2015, AJR. American journal of roentgenology.

Prevention and treatment of musculoskeletal disease in the haemophilia population: role of prophylaxis and synovectomy

V. Blanchette, K. Fischer, H. M. van den Berg, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Measurement of joint health in persons with haemophilia: A systematic review of the measurement properties of haemophilia‐specific instruments

V. Blanchette, K. Fischer, M. Peters, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

A systematic review of ultrasound imaging as a tool for evaluating haemophilic arthropathy in children and adults

V. Blanchette, T. Adams-Webber, A. Abadeh, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

A semiquantitative color Doppler ultrasound scoring system for evaluation of synovitis in joints of patients with blood-induced arthropathy

R. Moineddin, Yun Peng, V. Blanchette, 2021, Insights into Imaging.

Intracranial bleeding in haemophilia beyond the neonatal period – the role of CT imaging in suspected intracranial bleeding

V. Blanchette, M. Carcao, A. Stain, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Quantitative versus semiquantitative MR imaging of cartilage in blood-induced arthritic ankles: preliminary findings

F. Eckstein, R. Moineddin, V. Blanchette, 2014, Pediatric Radiology.

A systematic review of MR imaging as a tool for evaluating haemophilic arthropathy in children

V. Blanchette, E. Uleryk, S. Tadros, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Musculoskeletal measurement tools from the International Prophylaxis Study Group (IPSG)

R. Ljung, V. Blanchette, B. Feldman, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey

V. Blanchette, M. Carcao, Anthony K. C. Chan, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

Patterns of joint damage in severe haemophilia A treated with prophylaxis

S. Israels, V. Blanchette, M. Carcao, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Thromboelastography and thrombin generation assessments for pediatric severe hemophilia A patients are highly variable and not predictive of clinical phenotypes

V. Blanchette, M. Carcao, A. Stain, 2022, Research and practice in thrombosis and haemostasis.

Magnetic resonance imaging in boys with severe hemophilia A: Serial and end‐of‐study findings from the Canadian Hemophilia Primary Prophylaxis Study

S. Israels, V. Blanchette, M. Carcao, 2021, Research and practice in thrombosis and haemostasis.

Significant reduction in hemarthrosis in boys with severe hemophilia A: The China hemophilia individualized low‐dose secondary prophylaxis study

V. Blanchette, A. Abad, Zhenping Chen, 2021, Research and practice in thrombosis and haemostasis.

Assessments of outcome in haemophilia – what is the added value of QoL tools?

V. Blanchette, B. Feldman, K. Fischer, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada

P. Babyn, R. Moineddin, S. Israels, 2012, Journal of Thrombosis and Haemostasis.

Sonography for Assessment of Elbows in Hemophilic Children: A Systematic Protocol

V. Blanchette, A. Mohanta, A. Stain, 2012 .

Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study

P. Babyn, S. Israels, V. Blanchette, 2006, Journal of thrombosis and haemostasis : JTH.

Physical therapy and imaging outcome measures in a haemophilia population treated with factor prophylaxis: current status and future directions

P. Babyn, V. Blanchette, B. Feldman, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Critical appraisal of the International Prophylaxis Study Group magnetic resonance image scale for evaluating haemophilic arthropathy

V. Blanchette, M. Bordalo-Rodrigues, A. Dunn, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

North American prophylaxis studies for persons with severe haemophilia: background, rationale and design

V. Blanchette, M. Manco‐Johnson, 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

Unresolved issues in prophylaxis

J. Astermark, C. Leissinger, V. Blanchette, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

The Hemophilia Joint Health Score version 2.1 Validation in Adult Patients Study: A multicenter international study

C. Hermans, V. Blanchette, A. Abad, 2022, Research and practice in thrombosis and haemostasis.

Clinical outcomes in hemophilia: Towards development of a core set of standardized outcome measures for research

V. Blanchette, A. Abad, B. Feldman, 2020, Research and practice in thrombosis and haemostasis.

Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study

S. Israels, V. Blanchette, M. Poon, 2013, Journal of thrombosis and haemostasis : JTH.

Plasma and albumin‐free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients

G. Spotts, V. Blanchette, I. Warrier, 2008, Journal of thrombosis and haemostasis : JTH.

Development of a health‐related quality of life measure for boys with haemophilia: the Canadian Haemophilia Outcomes – Kids Life Assessment Tool (CHO‐KLAT)

V. Blanchette, N. Young, C. Bradley, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Redefining prophylaxis in the modern era

V. Blanchette, J. Mahlangu, R. Klamroth, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Patient‐relevant health outcomes for hemophilia care: Development of an international standard outcomes set

A. Iorio, V. Blanchette, B. Konkle, 2021, Research and practice in thrombosis and haemostasis.

PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors.

V. Jiménez‐Yuste, T. Lambert, M. Morfini, 2012, Thrombosis Research.

When should prophylaxis therapy in inhibitor patients be considered?

V. Jiménez‐Yuste, T. Lambert, M. Morfini, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates

A. Iorio, M. Morfini, V. Blanchette, 2017, Thrombosis and Haemostasis.

A Systematic Review of Ultrasound Imaging As a Tool for Evaluating Hemophilic Arthropathy in Children and Adults

V. Blanchette, T. Adams-Webber, A. Abadeh, 2015 .

Measuring activities and participation in persons with haemophilia: A systematic review of commonly used instruments

V. Blanchette, B. Feldman, M. Pisters, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Defining extended half‐life rFVIII—A critical review of the evidence

C. Hermans, E. Santagostino, V. Blanchette, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Updating the Canadian hemophilia outcomes-kids life assessment tool (CHO-KLAT Version2.0).

V. Blanchette, N. Young, C. Wakefield, 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring

G. Spotts, V. Blanchette, K. Fischer, 2010, Journal of thrombosis and haemostasis : JTH.

How well does the Canadian haemophilia Outcomes‐Kids' Life Assessment Tool (CHO‐KLAT) measure the quality of life of boys with haemophilia?

V. Blanchette, N. Young, C. Bradley, 2006, Pediatric blood & cancer.

Are randomized clinical trials the only truth? Not always

R. Ljung, V. Blanchette, L. Aledort, 2006, Journal of thrombosis and haemostasis : JTH.

The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B.

V. Blanchette, C. Rothschild, C. Négrier, 2005, Blood.

Pharmacokinetics of recombinant factor VIII (Kogenate‐FS®) in children and causes of inter‐patient pharmacokinetic variability

V. Blanchette, M. Carcao, D. Lillicrap, 2006 .

Novel and Clinically Significant Factors Influencing the Pharmacokinetic Variability of Recombinant Factor VIII (Kogenate-FS) in Children.

V. Blanchette, M. Carcao, D. Lillicrap, 2004 .

Managing Hemophilia in Children and Adolescents

V. Blanchette, J. Robertson, J. Curtin, 2013 .

Internal and External Determinants of Bleeding Patterns on Prophylaxis for Severe Haemophilia A.

J. Astermark, G. Spotts, V. Blanchette, 2007 .

Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis Study

S. Israels, V. Blanchette, B. Feldman, 2020, Research and practice in thrombosis and haemostasis.

Insight into health‐related quality of life of young children with haemophilia B treated with long‐acting nonacog beta pegol recombinant factor IX

E. Santagostino, V. Blanchette, N. Young, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Clinical and cost implications of target joints in Canadian boys with severe hemophilia A.

T. Einarson, V. Blanchette, B. Feldman, 2004, The Journal of pediatrics.

Cost‐utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on‐demand therapy in young children with severe haemophilia A

V. Blanchette, B. Feldman, N. Risebrough, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

Validity of the Portuguese CHO‐KLAT in Brazil

J. Carneiro, V. Blanchette, M. Ozelo, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

A Canadian survey of self‐infusion practices in persons with haemophilia A

V. Blanchette, R. Klaassen, B. Ritchie, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Securing reimbursement for patient centered haemophilia care: major collaborative efforts are needed

V. Blanchette, B. Feldman, K. Fischer, 2016, Haematologica.

Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study.

B. Kerlin, R. Ljung, V. Blanchette, 2020, Thrombosis Research.

Describing the quality of life of boys with haemophilia in China: Results of a multicentre study using the CHO‐KLAT

V. Blanchette, N. Young, R. Wu, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Effect of intracranial bleeds on the health and quality of life of boys with hemophilia.

M. Barnes, M. Golomb, V. Blanchette, 2004, The Journal of pediatrics.

Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis

G. Spotts, V. Blanchette, B. Konkle, 2020, Thrombosis and Haemostasis.

Comparative pharmacokinetics of two extended half‐life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?

A. Iorio, M. Morfini, V. Blanchette, 2019, Journal of thrombosis and haemostasis : JTH.

The economics of haemophilia prophylaxis: governmental and insurer perspectives. PROCEEDINGS OF THE SECOND INTERNATIONAL PROPHYLAXIS STUDY GROUP (IPSG) SYMPOSIUM

M. Bullinger, P. Giangrande, V. Blanchette, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Characterization of the Pharmacokinetics of rFVIII in Young Pre-School Children with Hemophilia, Including an Analysis of the Influence of Age and Body Weight.

G. Spotts, V. Blanchette, A. Shapiro, 2004 .

Hyperkalemia after neonatal exchange transfusion: risk eliminated by washing red cell concentrates.

S. MacMurray, H. Heick, V. Blanchette, 1984, The Journal of pediatrics.

Generic and disease-specific quality of life among youth and young men with Hemophilia in Canada

V. Blanchette, N. Young, R. Klaassen, 2016, BMC Hematology.

An International Prophylaxis Study Group (IPSG) survey of prophylaxis in inhibitor positive children/adults with severe haemophilia

C. Leissinger, V. Blanchette, M. Carcao, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

An International Prophylaxis Study Group (IPSG) survey of prophylaxis in adults with severe haemophilia

C. Leissinger, V. Blanchette, M. Carcao, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects

J. Blatny, M. Morfini, V. Blanchette, 2021, Thrombosis and Haemostasis.

Impact of prophylaxis on health‐related quality of life of boys with hemophilia: An analysis of pooled data from 9 countries

L. Tang, J. Carneiro, V. Blanchette, 2019, Research and practice in thrombosis and haemostasis.

Cost of severe haemophilia in Toronto

T. Einarson, V. Blanchette, B. Feldman, 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

Use of a Population Pharmacokinetic Model of ADVATE In Pediatric and Adult Patients with Hemophilia A Permits Limited Blood Sampling for Individual Dose Tailoring

G. Spotts, V. Blanchette, K. Fischer, 2010 .

Pilot study of once‐a‐day prophylaxis for youth and young adults with severe haemophilia A

V. Blanchette, M. Carcao, A. Abad, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Effect of Normal Variation in Factor VIII Pharmacokinetics on Prophylactic Dosing Requirements in Severe Classical Hemophilia.

G. Spotts, V. Blanchette, K. Fischer, 2008 .

Childhood acute immune thrombocytopenic purpura: 20 years later.

V. Blanchette, M. Carcao, 2003, Seminars in thrombosis and hemostasis.

Cross-cultural adaptation and validation of the Canadian Haemophilia Outcomes-Kids’ Life Assessment Tool (CHO-KLAT) in Côte d’Ivoire (the Ivory Coast)

C. Hermans, V. Blanchette, N. Young, 2020, Health and Quality of Life Outcomes.

C. Terwee, V. Blanchette, N. Young, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Clinical evaluation of an advanced category recombinant FVIII, anti-hemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM) in pediatric previously treated patients (PTPs)

G. Spotts, V. Blanchette, L. Navale, 2003 .

The Canadian Hemophilia Registry as the basis for a national system for monitoring the use of factor concentrates

A. Giles, S. Israels, V. Blanchette, 1995, Transfusion.

Hepatitis C infection in children with hemophilia A and B.

E. Wang, V. Blanchette, M. Petric, 1991, Blood.

Immunoadsorption may provide a cost‐effective approach to management of patients with inhibitors to FVIII

John Freedman, J. Freedman, V. Blanchette, 2003, Transfusion.

Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study

L. Tang, V. Blanchette, Zhenping Chen, 2018, Chinese medical journal.

Modeling Minimally-Effective FVIII Trough Levels in Hemophilia a Patients on PK-Guided Prophylaxis

G. Spotts, L. Valentino, V. Blanchette, 2014 .

In vitro and in vivo stability of diluted recombinant factor VIII for continuous infusion use in haemophilia A

V. Blanchette, S. Revel-Vilk, D. Lillicrap, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Acquired von Willebrand factor deficiency during high‐dose infusion of recombinant factor VIII

V. Blanchette, C. Sparling, G. Rock, 1996, British journal of haematology.

Reliability and Reproducibility of Classification of Children as “Bleeders” Versus “Non-Bleeders” Using a Questionnaire for Significant Mucocutaneous Bleeding

V. Blanchette, S. Revel-Vilk, D. Lillicrap, 2004, Journal of pediatric hematology/oncology.

Intracranial haemorrhage in von Willebrand disease: a report on six cases

V. Blanchette, M. Carcao, A. Stain, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

The changing face of hepatitis in boys with haemophilia associated with increased prevalence of obesity

V. Blanchette, S. Ling, S. Revel-Vilk, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Hemophilia Prophylaxis No Longer Just for Children without Inhibitors - Increasing Use of Prophylaxis in Other Groups (children with inhibitors and adults with and without inhibitors)

C. Leissinger, T. Lambert, E. Santagostino, 2015 .

Safety of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors: overall rFVIIa exposure and intervals following high (>240 μg kg−1) rFVIIa doses across clinical trials and registries

E. Neufeld, D. Cooper, V. Blanchette, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Hepatitis C Infection in Patients With Hemophilia: Results of a National Survey

V. Blanchette, R. Roberts, I. Walker, 1994 .

Guidelines for auditing pediatric blood transfusion practices.

R. Strauss, V. Blanchette, N. Luban, 1991, American journal of diseases of children.

PPT5: LONG TERM COST OF ILLNESS STUDY FOR SEVERE HEMOPHILIC CHILDREN IN TORONTO

T. Einarson, V. Blanchette, B. Feldman, 2003 .

10 Year Musculoskeletal Outcomes with Tailored Primary Prophylaxis: The Canadian Hemophilia Prophylaxis Study.

S. Israels, V. Blanchette, B. Feldman, 2007 .

Population Pharmacokinetic Model of ADVATE in Pediatric and Adult Patients with Hemophilia A.

G. Spotts, V. Blanchette, K. Fischer, 2009 .

The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B

A. Iorio, V. Blanchette, M. Carcao, 2021, Research and practice in thrombosis and haemostasis.

The value of usability testing for Internet-based adolescent self-management interventions: “Managing Hemophilia Online”

Jennifer N. Stinson, Vicky R. Breakey, Ashley V. Warias, 2013, BMC Medical Informatics and Decision Making.

Exploring internet needs and use among adolescents with haemophilia: a website development project

V. Blanchette, V. Breakey, J. Nyhof-Young, 2012, Haemophilia.

Process and experience of cross‐cultural adaptation of a quality of life measure (CHO‐KLAT) for boys with haemophilia in Brazil

J. Carneiro, V. Blanchette, P. Villaça, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Social participation and hemophilia: Self‐perception, social support, and their influence on boys in Canada

V. Blanchette, N. Young, A. Abad, 2021, Research and practice in thrombosis and haemostasis.

Pediatric Thrombosis and Hemostasis: A Historical Perspective

V. Blanchette, V. Breakey, 2013 .

Recombinant factor VIII in hemophilia A: the Canadian experience.

V. Blanchette, 1997, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Measuring the impact of changing from standard half‐life (SHL) to extended half‐life (EHL) FVIII prophylaxis on health‐related quality of life (HRQoL) in boys with moderate/severe haemophilia A: Lessons learned with the CHO‐KLAT tool

V. Blanchette, N. Young, M. Carcao, 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

Hemophilia during pregnancy.

G. Koren, R. Goldman, V. Blanchette, 2003, Canadian family physician Medecin de famille canadien.

Development of Disease-Specific Health-Related Quality-of-Life Instruments for Children With Immune Thrombocytopenic Purpura and Their Parents

D. Feeny, J. Bussel, V. Blanchette, 2003, Journal of pediatric hematology/oncology.

Systematic Review of the Published Evidence on the Pharmacokinetic Characteristics of Factor VIII and IX Concentrates

E. Neufeld, A. Iorio, C. Hermans, 2014 .

A Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Study to Determine the Effect of Romiplostim on Health‐Related Quality of Life in Children with Primary Immune Thrombocytopenia and Associated Burden in Their Parents

V. Blanchette, R. Crosby, Xiaoyan Li, 2016, Pediatric blood & cancer.

Importance of literacy for self‐reported health‐related quality of life: a study of boys with haemophilia in Brazil

J. Carneiro, V. Blanchette, P. Villaça, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Cross-cultural adaptation of the CHO-KLAT for boys with hemophilia in rural and urban china

Jishui Zhang, V. Blanchette, N. Young, 2012, Health and Quality of Life Outcomes.

Cross‐cultural validation of the CHO‐KLAT and HAEMO‐QoL‐A in Canadian French

V. Blanchette, N. Young, L. Hershon, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Modelling FVIII Levels for Prediction of Zero Spontaneous-Joint Bleeding in a Cohort of Severe Hemophilia a Subjects with Target Joints Initiated on Tertiary Prophylaxis

G. Spotts, L. Valentino, V. Blanchette, 2016 .

Characterization of platelet‐reactive antibodies in children with varicella‐associated acute immune thrombocytopenic purpura (ITP)

J. Freedman, V. Blanchette, M. Petric, 1996, British journal of haematology.

Effect of intracranial bleeds on the neurocognitive, academic, behavioural and adaptive functioning of boys with haemophilia

M. Barnes, M. Golomb, V. Blanchette, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Utility of factor VIII and factor VIII to von Willebrand factor ratio in identifying 277 unselected carriers of hemophilia A

V. Blanchette, M. Carcao, V. Bouskill, 2017, American journal of hematology.

Use of a quantitative pediatric bleeding questionnaire to assess mucocutaneous bleeding symptoms in children with a platelet function disorder

V. Blanchette, P. James, T. Biss, 2010, Journal of thrombosis and haemostasis : JTH.

International consensus report on the investigation and management of primary immune thrombocytopenia.

Drew Provan, Robert McMillan, Shirley Watson, 2010, Blood.

Guidelines on the use of intravenous immune globulin for hematologic conditions.

V. Blanchette, M. Brouwers, L. Huebsch, 2007, Transfusion medicine reviews.

Bleeding assessment tools to predict von Willebrand disease: Utility of individual bleeding symptoms

A. Paterson, Yupu Liang, B. Coller, 2019, Research and practice in thrombosis and haemostasis.

Generation and optimization of the self‐administered pediatric bleeding questionnaire and its validation as a screening tool for von Willebrand disease

V. Blanchette, P. Moorehead, R. Klaassen, 2017, Pediatric blood & cancer.

9 Haematological investigation in neonates

V. Blanchette, M. Andrew, J. Doyle, 1990 .

Clinical trial design in haemophilia

V. Blanchette, E. Berntorp, D. DiMichele, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Glanzmann thrombasthenia platelets compete with transfused platelets, reducing the haemostatic impact of platelet transfusions

V. Blanchette, M. Carcao, V. Bouskill, 2018, British journal of haematology.

Platelet disorders in newborn infants: diagnosis and management.

V. Blanchette, M. Rand, 1997, Seminars in perinatology.

Recurring mutations at CpG dinucleotides in the region of the von Willebrand factor gene encoding the glycoprotein Ib binding domain, in patients with type IIB von Willebrand's disease

A. Giles, V. Blanchette, D. Lillicrap, 1991, British Journal of Haematology.

Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and meta-analysis of randomized controlled trials.

P. Nathan, C. Macarthur, V. Blanchette, 2005, The Journal of pediatrics.

Role of intravenous immunoglobulin G in autoimmune hematologic disorders.

V. Blanchette, C. Turner, M. Kirby, 1992, Seminars in hematology.

High-dose intravenous gammaglobulin therapy for neonatal autoimmune thrombocytopenia.

V. Blanchette, M. Andrew, M. Perlman, 1988, The Journal of pediatrics.

Front & Back Matter

C. Steinlein, W. Wiersinga, T. Haaf, 2019, Cytogenetic and Genome Research.

Fcgamma receptor IIa and IIIa polymorphisms in childhood immune thrombocytopenic purpura.

V. Blanchette, M. Carcao, G. Denomme, 2003, British journal of haematology.

Characterization of HIV‐1‐specific antibodies and HIV‐1‐crossreactive antibodies to platelets in HIV‐1‐infected haemophiliac patients

J. Freedman, V. Blanchette, W. Chia, 1998, British journal of haematology.

Validation and reliability of a disease‐specific quality of life measure (the TranQol) in adults and children with thalassaemia major

E. Neufeld, E. Vichinsky, V. Blanchette, 2014, British journal of haematology.

Quantitative Platelet Disorders

V. Blanchette, W. Kahr, J. Robertson, 2010 .

Self-Reported Initial Management of Childhood Idiopathic Thrombocytopenic Purpura: Results of a Survey of Members of the American Society of Pediatric Hematology/Oncology, 2001

S. Vesely, J. George, V. Blanchette, 2003, Journal of pediatric hematology/oncology.

A multicenter study of the treatment of childhood chronic idiopathic thrombocytopenic purpura with anti-D.

S. Israels, V. Blanchette, M. Andrew, 1992, The Journal of pediatrics.

A laparoscopic approach to partial splenectomy for children with hereditary spherocytosis

V. Blanchette, J. Langer, V. Price, 2006, Surgical Endoscopy And Other Interventional Techniques.

Laparoscopic partial vs total splenectomy in children with hereditary spherocytosis.

V. Blanchette, J. Langer, S. Dutta, 2008, Journal of pediatric surgery.

Rare Congenital Factor Deficiencies in Childhood

V. Blanchette, F. Xavier, 2013 .

Downregulation of the anti-HLA alloimmune response by variable region-reactive (anti-idiotypic) antibodies in leukemic patients transfused with platelet concentrates.

J. Freedman, M. Kazatchkine, V. Blanchette, 1993, Blood.

Anti-Idiotypic Regulation of the Alloimmune Response in Patients Transfused with Platelet Concentrates

M. Kazatchkine, V. Blanchette, J. Semple, 1993 .

Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study

V. Blanchette, P. Bolton-Maggs, T. Kühne, 2001, The Lancet.

Shared Decision Making in the Management of Children With Newly Diagnosed Immune Thrombocytopenia

H. Llewellyn-Thomas, V. Blanchette, V. Breakey, 2014, Journal of pediatric hematology/oncology.

thrombocytopenic purpura Severe hemorrhage in children with newly diagnosed immune

S. Vesely, J. Neufeld, V. Blanchette, 2013 .

Chronic Immune Thrombocytopenic Purpura in Children: A Survey of the Canadian Experience

V. Blanchette, B. Ritchie, John Wu, 2007, Journal of pediatric hematology/oncology.

Front & Back Matter

L. Shaffer, C. Steinlein, G. Mortier, 2019, Molecular Syndromology.

Front & Back Matter

W. Wiersinga, G. Kahaly, V. Blanchette, 2019, Neuroimmunomodulation.

Alloimmunization to the PIA1 platelet antigen: results of a prospective study

V. Blanchette, F. Décary, V. Hogan, 1990, British journal of haematology.

Neonatal thrombocytopenia due to passive immunization: prenatal diagnosis and distinction between maternal platelet alloantibodies and autoantibodies.

P. Powers, V. Blanchette, R. Barr, 1980, The New England journal of medicine.

Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.

J. Bussel, V. Blanchette, L. Krishnamurti, 2015, The Lancet. Haematology.

Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group.

J. Bussel, V. Blanchette, D. Cines, 2013, Blood.

Pilot study of the effect of romiplostim on child health‐related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP)

J. Bussel, V. Blanchette, N. Young, 2012, Pediatric blood & cancer.

Childhood immune thrombocytopenic purpura: diagnosis and management.

V. Blanchette, P. Bolton-Maggs, 2008, Pediatric clinics of North America.

Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia

A. Raj, J. Bussel, V. Blanchette, 2019, Haematologica.

Immune thrombocytopenia following successful treatment of cancer in children

V. Blanchette, M. Greenberg, P. Canning, 2006, Pediatric blood & cancer.

A Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP)

J. Bussel, V. Blanchette, M. Tarantino, 2016 .

Neonatal alloimmune thrombocytopenia due to a new platelet-specific alloantibody.

V. Blanchette, R. Aster, P. Newman, 1993, Blood.

IVMP+IVIG raises platelet counts faster than IVIG alone: results of a randomized, blinded trial in childhood ITP.

V. Blanchette, M. Carcao, R. Klaassen, 2020, Blood advances.

Relationships among bleeding severity, health‐related quality of life, and platelet count in children with immune thrombocytopenic purpura

V. Blanchette, N. Young, R. Klaassen, 2009, Pediatric blood & cancer.

V. Blanchette, M. Axford, S. Dell, 2018, Clinical genetics.

Front & Back Matter

W. Wiersinga, G. Kahaly, V. Blanchette, 2018, Acta Haematologica.

J. Bussel, V. Blanchette, J. Grainger, 2019, British journal of haematology.

Front & Back Matter

L. Shaffer, C. Steinlein, G. Coukos, 2017, Molecular Syndromology.

Prenatal diagnosis and management of neonatal alloimmune thrombocytopenia.

V. Blanchette, G. Ryan, A. Al-Musa, 1997, Seminars in perinatology.

A Randomized, Double-Blind, Placebo-Controlled Phase 1/2 Study to Determine the Safety and Efficacy of Romiplostim in Children with Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP).

J. Bussel, V. Blanchette, G. Buchanan, 2009 .

Management of Alloimmune Neonatal Thrombocytopenia

V. Blanchette, M. Rand, J. Johnson, 1989, The Lancet.

Alloimmune thrombocytopenia.

V. Blanchette, K. Pegg-Feige, M. A. Peters, 1986, American journal of perinatology.

Decreased numbers of dense granules in fetal and neonatal platelets

D. Chitayat, V. Blanchette, P. Shah, 2017, Haematologica.

Very early thrombocytopenia in neonatal alloimmune thrombocytopenia

J. Freedman, A. Toi, V. Blanchette, 1993 .

Neonatal autoimmune thrombocytopenia: role of high-dose intravenous immunoglobulin G therapy

V. Blanchette, M. Andrew, M. Perlman, 1989, Blut.

Intensive plasma exchange therapy in ten patients with idiopathic thrombocytopenic purpura

V. Blanchette, J. Bormanis, J. Drouin, 1984, Transfusion.

Quality of life in immune thrombocytopenia following treatment

V. Blanchette, N. Young, R. Klaassen, 2013, Archives of Disease in Childhood.

Quality of life in childhood immune thrombocytopenia: International validation of the kids' ITP tools

G. Gaedicke, V. Blanchette, N. Young, 2013, Pediatric Blood & Cancer.

Long-term outcomes after splenectomy in children with immune thrombocytopenia: an update on the registry data from the Intercontinental Cooperative ITP Study Group

V. Blanchette, E. Pullenayegum, M. L. Avila, 2019, Haematologica.

Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS).

S. Vesely, E. Neufeld, V. Blanchette, 2009, Blood.

Front & Back Matter

G. Coukos, M. Saier, W. Mieler, 2017, Journal of Molecular Microbiology and Biotechnology.

Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchange. Canadian Apheresis Study Group.

J. Kelton, V. Blanchette, R. Spasoff, 1992, Transfusion.

Baseline characteristics and outcomes of children with cancer in the English‐speaking Caribbean: A multinational retrospective cohort

C. Bodkyn, V. Blanchette, U. Allen, 2018, Pediatric blood & cancer.

Kasabach–Merritt phenomenon: a single centre experience

S. Mahant, S. Baruchel, V. Blanchette, 2010, European journal of haematology.

Response to Steroids Predicts Response to Rituximab In Pediatric Chronic Immune Thrombocytopenia.

L. Kalish, E. Neufeld, C. Thornburg, 2010 .

A variant form of Bernard-Soulier syndrome: mild haemostatic defect associated with partial platelet GPIb deficiency.

M. Stevens, V. Blanchette, T. Kunicki, 1988, Clinical and Laboratory Haematology.

Hodgkin's disease in children: treatment with MOPP and low-dose, extended field irradiation without laparotomy. Late results and toxicity.

T. Panzarella, V. Blanchette, M. Greenberg, 1990, Medical and pediatric oncology.

Congenital hypopituitarism and conjugated hyperbilirubinemia in two infants.

P. A. Lee, L. Plotnick, V. Blanchette, 1978, American journal of diseases of children.

Longitudinal investigation of neuropsychological functioning in children and adolescents with hemophilia and HIV infection

M. Smith, V. Blanchette, C. Netley, 1997 .

Antiplatelet antibody detection in alloimmunized patients with acute leukaemia

J. Freedman, V. Blanchette, M. Garvey, 1996 .

Blood component therapy during the neonatal period: a national survey of red cell transfusion practice, 1985

R. Strauss, V. Blanchette, N. Luban, 1990, Transfusion.

Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia

E. Neufeld, C. Thornburg, V. Blanchette, 2012, Pediatric blood & cancer.

Front & Back Matter

W. Wiersinga, G. Kahaly, V. Blanchette, 2018, European Thyroid Journal.

Measuring disease-specific quality of life in rare populations: a practical approach to cross-cultural translation

V. Blanchette, N. Young, R. Klaassen, 2009, Health and quality of life outcomes.

Anti‐D (WinRho SD™) treatment of children with chronic autoimmune thrombocytopenic purpura stimulates transient cytokine/chemokine production

D. Allen, J. Freedman, V. Blanchette, 2002, American journal of hematology.

Front & Back Matter

W. Wiersinga, G. Kahaly, V. Blanchette, 2019, Acta Haematologica.

Treatment of acute idiopathic thrombocytopenic purpura.

V. Blanchette, C. Turner, 1986, The Journal of pediatrics.

Reply to: Short-term, high-dose corticosteroid therapy in childhood acute immune thrombocytopenic purpura

V. Blanchette, 1995 .

National acceptability of American Association of Blood Banks Pediatric Hemotherapy Committee guidelines for auditing pediatric transfusion practices

R. Strauss, V. Blanchette, H. Hume, 1993, Transfusion.

Updating the Canadian Hemophilia Outcomes–Kids’ Life Assessment Tool (CHO‐KLAT) in the era of extended half‐life clotting factor concentrates

V. Blanchette, N. Young, M. Carcao, 2021, Research and practice in thrombosis and haemostasis.

Preference-Based Measurement of Health-Related Quality of Life (HRQL) in Children with Chronic Musculoskeletal Disorders (MSKDs)

V. Blanchette, N. Young, B. Feldman, 2003, Medical decision making.

Rapid Assessment of Platelet Function Using Thromboelastography and Small Volumes of Citrated Whole Blood.

V. Blanchette, W. Kahr, F. Pluthero, 2005 .

Review of the literature on allogeneic red blood cell and plasma transfusions in children

V. Blanchette, J. Kronick, H. Hume, 1997 .

Front & Back Matter

W. Wiersinga, G. Kahaly, V. Blanchette, 2019, Folia primatologica.

Validity, reliability, and responsiveness of a new measure of health-related quality of life in children with immune thrombocytopenic purpura: the Kids' ITP Tools.

E. Neufeld, V. Blanchette, N. Young, 2007, The Journal of pediatrics.

Validation of the school age self‐administered pediatric bleeding questionnaire (Self‐PBQ) in children aged 8–12 years

V. Blanchette, N. Barrowman, R. Klaassen, 2019, Pediatric blood & cancer.

Expanded phenotype–genotype correlations in a pediatric population with type 1 von Willebrand disease

V. Blanchette, M. Carcao, P. James, 2011, Journal of thrombosis and haemostasis : JTH.

Phosphatidylserine exposure and other apoptotic‐like events in Bernard‐Soulier syndrome platelets

J. Freedman, V. Blanchette, J. Teitel, 2010, American journal of hematology/oncology.

Pain Perception and Effectiveness of the Eutectic Mixture of Local Anesthetics in Children Undergoing Venipuncture

G. Koren, V. Blanchette, N. Olivieri, 1992, Pediatric Research.

Megakaryocyte and platelet abnormalities in a patient with a W33C mutation in the conserved SH3-like domain of myosin heavy chain IIA

J. Forman-Kay, A. Savoia, V. Blanchette, 2009, Thrombosis and Haemostasis.

A survey of Canadian neonatal blood transfusion practices.

R. Strauss, V. Blanchette, H. Hume, 1997, Transfusion science.

Platelet-Surface Glycoproteins in Healthy and Preeclamptic Mothers and Their Newborn Infants

J. Freedman, V. Blanchette, G. Ryan, 1996, Pediatric Research.

Front & Back Matter

W. Wiersinga, G. Kahaly, V. Blanchette, 2019, Ophthalmic Research.

Platelet activation and hypercoagulability following treatment with porcine factor VIII (HYATE:C)

J. Freedman, V. Blanchette, A. Lazarus, 2002, American journal of hematology.

Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A

J. Astermark, G. Spotts, V. Blanchette, 2009, Journal of thrombosis and haemostasis : JTH.

PETIT and PETIT 2: Treatment with Eltrombopag in 171 Children with Chronic Immune Thrombocytopenia (ITP)

J. Bussel, V. Blanchette, F. Locatelli, 2014 .

Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A

V. Blanchette, M. Carcao, J. Leggo, 2003, Journal of thrombosis and haemostasis : JTH.

An MRI scale for assessment of haemophilic arthropathy from the International Prophylaxis Study Group

R. Moineddin, M. Manco-Johnson, R. Ljung, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Quantitation of Bleeding Symptoms in Children with von Willebrand Disease (VWD) or a Platelet Function Disorder: Use of a Standardized Pediatric Bleeding Score.

V. Blanchette, P. James, D. Lillicrap, 2007 .

Symposium on neonatal transfusion practices.

V. Blanchette, H. Hume, 1995, Transfusion Medicine Reviews.

A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres

V. Blanchette, G. Rivard, M. Manco‐Johnson, 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH

V. Blanchette, M. Ozelo, K. Fischer, 2016, Journal of thrombosis and haemostasis : JTH.

Haemophilia

V. Blanchette, K. Fischer, A. Shapiro, 2021, Nature Reviews Disease Primers.

Hepatitis C infection in patients with hemophilia: results of a national survey. Canadian Hemophilia Clinic Directors Group.

V. Blanchette, R. Roberts, I. Walker, 1994, Transfusion Medicine Reviews.

Assessment of outcomes

V. Blanchette, J. Mahlangu, B. O’Mahony, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Identifying Children with HEreditary Coagulation disorders (iCHEC): a protocol for a prospective cohort study

J. H. van der Lee, M. Suijker, V. Blanchette, 2018, BMJ Open.

Development of a Thai version of the paediatric bleeding assessment tool (Thai paediatric‐BAT) suitable for use in children with inherited mucocutaneous bleeding disorders

V. Blanchette, M. Rand, P. Komwilaisak, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Evaluation of Bleeding Symptoms in Children with An Inherited Mucocutaneous Bleeding Disorder.

V. Blanchette, P. James, T. Biss, 2009 .

Measuring the impact of hemophilia on families: Development of the Hemophilia Family Impact Tool (H‐FIT)

V. Blanchette, N. Young, M. Carcao, 2021, Research and practice in thrombosis and haemostasis.

Growing Up with Hemophilia: Assessing Teens' Experiences and Needs During Transition to Adult Health Care

V. Blanchette, V. Breakey, J. Nyhof-Young, 2013 .

The Quality and Accuracy of Hemophilia Information on the Internet.

A. Denburg, V. Blanchette, V. Breakey, 2009 .

Approach to the investigation and management of immune thrombocytopenic purpura in children.

V. Blanchette, M. Carcao, V. Blanchette, 2000, Seminars in hematology.

Intravenous immunoglobulin G and anti-D as therapeutic interventions in immune thrombocytopenic purpura.

V. Blanchette, M. Carcao, V. Blanchette, 1998, Transfusion science.

Autoantibodies against platelet membrane glycoproteins in children with acute and chronic immune thrombocytopenic purpura.

V. Blanchette, P. Tani, R. Mcmillan, 1989, Blood.

Routine bleeding history and laboratory tests in children presenting with a renal mass

M. Coppes, V. Blanchette, 2009, Pediatric Blood & Cancer.

Clinical Implications of Pharmacokinetic Variables in the Management of Patients with Severe Hemophilia A.

J. Astermark, V. Blanchette, P. Collins, 2006 .

Directed and limited‐exposure blood donations for infants and children

R. Strauss, V. Blanchette, H. Hume, 1990, Transfusion.

Effect of Romiplostim on Health-Related Quality of Life in Children with Immune Thrombocytopenia and Associated Burden in Their Parents: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

V. Blanchette, R. Crosby, Xiaoyan Li, 2015 .

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of Romiplostim in Children with Immune Thrombocytopenia (ITP)

A. Raj, J. Bussel, V. Blanchette, 2015 .

a core set of outcome measurement tools in patients with hemophilia: a systematic review of the measurement properties : Po245-tue

V. Blanchette, A. Abad, B. Feldman, 2015 .

Intravenous immunoglobulin: more questions than answers.

V. Blanchette, R. Sacher, 1991, Transfusion medicine reviews.

Bridging the Distance in the Caribbean: Telemedicine as a means to build capacity for care in paediatric cancer and blood disorders.

S. Gupta, C. Bodkyn, V. Blanchette, 2015, Studies in health technology and informatics.

A cost‐effectiveness evaluation of platelet crossmatching and HLA matching in the management of alloimmunized thrombocytopenic patients

A. Gafni, V. Blanchette, M. Garvey, 1989, Transfusion.

Patterns of factor prophylaxis in the Canadian hemophilia A population

S. Israels, V. Blanchette, A. Stain, 2003 .

Recombinant FVIIa in the management of intracerebral haemorrhage in severe thrombocytopenia unresponsive to platelet‐enhancing treatment

V. Blanchette, M. Carcao, P. Canning, 2005, Transfusion medicine.

Prenatal diagnosis of neonatal alloimmune thrombocytopenia using an allele‐specific oligonucleotide probe

J. Freedman, V. Blanchette, J. Mcfarland, 1993, Prenatal diagnosis.

Mechanism of action of high-dose intravenous immunoglobulin therapy in immune thrombocytopenic purpura (ITP).

V. Blanchette, 章司久米, 1985 .

Phosphatidylserine exposure and other apoptotic‐like events in Bernard‐Soulier syndrome platelets

J. Freedman, V. Blanchette, J. Teitel, 2010, American journal of hematology.

Combined De-Novo Mutation and Non-Random X-Chromosome Inactivation Causing Wiskott-Aldrich Syndrome in a Female with Thrombocytopenia

S. Scherer, H. Ochs, T. Torgerson, 2013, Journal of Clinical Immunology.

Quality of life in childhood immune thrombocytopenia: International validation of the kids' ITP tools

G. Gaedicke, V. Blanchette, N. Young, 2013, Pediatric blood & cancer.

Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults

V. Blanchette, C. Négrier, S. Lethagen, 2023, Research and practice in thrombosis and haemostasis.

Definitions in Hemophilia: Resolved and Unresolved Issues

V. Blanchette, A. Srivastava, 2015, Seminars in Thrombosis & Hemostasis.

Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A

J. Astermark, G. Spotts, V. Blanchette, 2009, Journal of thrombosis and haemostasis : JTH.

When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH

V. Blanchette, M. Ozelo, K. Fischer, 2016, Journal of thrombosis and haemostasis : JTH.

A systematic review of MR imaging as a tool for evaluating haemophilic arthropathy in children

V. Blanchette, E. Uleryk, S. Tadros, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.